Hippocratic AI Adds Seasoned Leaders to Scale Safe Generative AI Healthcare Agents
Feb 11, 2026 - Palo Alto, CA. Hippocratic AI announced several executive appointments to accelerate platform adoption across providers, payors, and life sciences. The hires strengthen clinical leadership, operations, and go-to-market execution as demand increases. This move follows the company's $141 million Series C round in November and builds on a total of $404 million raised.
Why this matters for executives
Healthcare leaders want measurable outcomes, not hype. Hippocratic AI focuses on non-diagnostic, patient-facing agents designed to improve access, experience, and operational efficiency without prescribing or diagnosing. The new leaders bring clinical credibility and operational rigor-key ingredients for safe deployment and enterprise-scale rollouts.
New executive appointments
- Dr. Anoop Sangha, MD - Associate Chief Medical Officer
More than two decades in clinical practice and physician leadership across Transcarent, Livongo (Teladoc Health), Optum, and the Advisory Board Company. He has scaled AI-enabled care models, remote patient monitoring, and programs in navigation, chronic care, and population health. Known for uniting clinical rigor with product, operations, and commercial strategy to drive outcomes. - Dr. Eduardo Reis, MD - Vice President, Strategy (Office of the CEO)
Neuroradiologist and AI researcher with leadership and research roles at Stanford's Center for Artificial Intelligence in Medicine and Imaging (AIMI) and Hospital Israelita Albert Einstein. Recently served as Founding Radiologist at a fast-growing radiology AI startup acquired by a large radiology group. Brings deep expertise in building, evaluating, and deploying medical AI for real-world use to inform executive strategy and product development. - Niloy Sanyal - Chief Marketing Officer
20+ years growing healthcare, AI, and enterprise SaaS companies at LeanTaaS, Omnicell, and GE Digital. Led global marketing and go-to-market functions, launched enterprise platforms, and partnered with product and sales to drive sustained adoption. Recognized for translating complex tech into clear value propositions and building high-performing teams.
Strategic implications
For health systems and payors, these hires signal a push from pilots to scaled deployments: patient outreach, care navigation, chronic condition support, and operational workflows where safety, consistency, and unit economics matter. Hippocratic AI's stance is clear-patient-facing agents with guardrails, clinical oversight, and measurable utility. Expect tighter integration with existing workflows, stronger evaluation frameworks, and more rigorous governance aligned with industry guidance such as the NIST AI Risk Management Framework, and with compliance pathways familiar to regulatory teams (AI Learning Path for Regulatory Affairs Specialists).
What to watch next
- Clinical and operational outcomes tied to agent-supported programs (navigation, RPM, population health).
- Health system and payor partnerships that move beyond proofs of concept to sustained rollouts.
- Safety guardrails and external validation methods used before and after deployment.
- Go-to-market focus across providers, payors, and life sciences, plus unit economics at scale.
About Hippocratic AI
Hippocratic AI builds what it positions as the safest generative AI agents for healthcare, focused on non-diagnostic, patient-facing use cases. The company does not allow its agents to prescribe or diagnose. Backers include Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at hippocraticai.com.
For executives building AI capability across teams, consider role-based upskilling such as the AI Learning Path for VPs of Strategy or the AI Learning Path for CIOs.
Your membership also unlocks:
